

May 28, 2015

Hello,

If you are looking for a high profile opportunity to demonstrate national leadership and are seeking ways to impact the care that is delivered to Canadians with cancer, consider this exciting role to participate in the pan-Canadian Oncology Drug Review (pCODR) to make cancer drug funding recommendations to participating provincial/territorial Ministries of Health and provincial cancer agencies to help guide their cancer drug funding decisions.

pCODR is recruiting a [Chair \(Elect\) for the pCODR Expert Review Committee \(pERC\)](#), as part of the succession plan for our inaugural Chair's departure in 2016. We are very grateful for Dr. Anthony Fields' visionary and exceptional leadership of pERC. In the five years of the committee's function, pERC has gained the respect of both cancer control and health technology assessment communities alike.

The Chair Elect is expected to begin approximately mid-October 2015 for a six to twelve month term. The precise start date of the term is negotiable and will be guided by the successful candidate's skills and past experiences relevant to the role. The term for Chair will begin by mid-October 2016 and continue for a period of three years.

The [nomination package for pERC Chair](#) provides a clear outline of the criteria and process to become pERC Chair (Elect). Nominations/submissions for the pERC Chair (Elect) position will be accepted until 5 p.m. EDT, June 29, 2015.

Please note that [other positions for pERC](#) are also currently under active recruitment as part of the planned committee renewal process.

Also, pCODR continuously recruits [oncologists](#) to sit on the 11 clinical guidance panels, which are structured around specific tumour types, e.g. breast, endocrine, gastrointestinal, genitourinary, head and neck, leukemia, lymphoma and myeloma, lung, melanoma, neuro-oncology, sarcoma. We are also in need of [economists](#), with knowledge of pharmacoeconomics, to participate on the economic guidance panels.

For information about the different opportunities available with pCODR, a program of CADTH, including for the pERC Chair, other positions on pERC, as well as becoming members of the Clinical and/or Economic Guidance Panels, please visit our website at <https://www.cadth.ca/pcodr/call-for-nominations>

If you have any questions, please contact us at nominations@pcodr.ca

About pCODR

The pan-Canadian Oncology Drug Review (pCODR), a CADTH program, assesses cancer drugs and makes reimbursement recommendations to the provinces and territories to guide their drug funding decisions. pCODR is designed to bring consistency and clarity to the assessment of cancer drugs by looking at clinical evidence, cost-effectiveness, and patient perspectives.

Sincerely,

- original signed -

Mona Sabharwal
Executive Director